GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $21.27B |
| Gross Profit (TTM) | $8.41B |
| EBITDA | $3.59B |
| Operating Margin | 15.00% |
| Return on Equity | 19.40% |
| Return on Assets | 5.13% |
| Revenue/Share (TTM) | $46.79 |
| Book Value | $24.30 |
| Price-to-Book | 2.87 |
| Price-to-Sales (TTM) | 1.47 |
| EV/Revenue | 1.879 |
| EV/EBITDA | 10.81 |
| Quarterly Earnings Growth (YoY) | 16.80% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $454.89M |
| Float | $450.22M |
| % Insiders | 0.35% |
| % Institutions | 94.15% |
Volatility is currently contracting
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.
GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock?
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference: Wells Fargo 21st Annual Health Conference – Wednesday, September 9, 2026 at 10:15 am ET/9:15am CT A webcast for the event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events at the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global health.
GEHC's 11.1% order growth and record $23.9B backlog improve revenue visibility, but PCS execution and inflation remain key constraints.
GEHC's valuation discount and growth in imaging and diagnostics support the case, but PCS weakness, inflation and debt keep execution risks elevated.
GE HealthCare's record backlog, strong Pharmaceutical Diagnostics growth and AI innovation support its growth outlook despite margin pressures.
LOS ANGELES, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GEHC and any ticker you trade — then tracks every position and per-strategy win rate.
